HIF1A and cancer: A recent study has revealed an intriguing discovery that drug-resistant residual cells in microscopic residual disease of breast cancer exhibit similar DNA methylation status as cancer cells, regardless of lacking proliferative phenotypes and oncogenic signals.415 Notably, the promoter regions of HIF-1α, which is commonly recognized as an active master modulator of tumor glycolysis, displayed a comparable DNA methylation profile.